June 16 - A second Duchenne death, Sage’s ‘unremarkable’ end and the FDA’s ‘resource constraints’

Sage, following Setbacks, to sell to Supernus for $561M; Biotech’s M&A outlook is uncertain. Track the deals that are happening here.; FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

View online | Signup

Daily Dive

June 16, 2025 | Today’s news and insights for biopharma leaders

BROUGHT TO YOU BY — BioPharma Dive’s studioID

How Drugmakers Achieve Patient-Centric Development

Learn how prioritizing patient insights, communication, and diversity can make a lasting difference in treatment development in this infographic.

Second Duchenne patient dies after receiving Sarepta gene therapy

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain patients while it evaluates new safety precautions.

Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.

UPDATED

Biotech’s M&A outlook is uncertain. Track the deals that are happening here.

Supernus’ buyout of Sage involves a share price premium that’s among the lowest paid by an acquirer this year.

Unlock the benefits of direct-to-patient clinical supply

Catalent FlexDirect® allows clinical supplies to be delivered directly to patients’ homes, minimizing or removing the need for clinical site visits.
Discover more about DTP.

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.

From Our Library

Playbook

What We’re Reading

Fierce Biotech